Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2003

View Archived Issues

XenoPort and Alza combine technologies in collaboration

Evotec and Oxagen enter drug discovery alliance

Cephalon and MDS Proteomics enter drug discovery research collaboration

Peregrine and Schering collaborate to develop vascular targeting agents

Several series of delta opioid receptor agonists prepared and tested at AstraZeneca

Novel inhibitors of VLA-4-mediated cell adhesion described in recent patent

Sumitomo patents series of antidiabetic piperazines

Pyrrole-based agents for epilepsy and neuropathic pain identified at Ortho-McNeil

Novel apoptosis inhibitors with utility in cancer and other disorders

Senju researchers describe novel antibacterial PDF inhibitors

Bicyclic factor Xa inhibitors designed by BMS scientists

Possible treatment for IgA nephropathy being developed by CuraGen and Abgenix

Inspire prepares to submit NDA for diquafosol by mid-2003

AME-359 protects rats from cocaine overdose

Safinamide plus dopamine agonist therapy improves motor scores in PD

Chiron partners with GlaxoSmithKline for obesity program

Purdue licenses Corixa antigen

Canadian phase I trial of Infecton imaging agent cleared to begin

Phase I/II results announced for Genzyme Molecular Oncology's melanoma vaccine

Senexis receives start-up funding from BTG and Catalyst BioMedica

Celltech relaunches Dipentum

Human Genome Sciences updates pipeline progress

BAL-9141: potency and spectrum of activity tested against large number of clinical isolates

Safety of WHI-05 and WHI-07 demonstrated preclinically

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...